6-K - Basel Medical Group Ltd (0002004489) (Filer)

NT 20-F - Basel Medical Group Ltd (0002004489) (Filer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

Singapore, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL) (the "Company"), today announced that it has received notification from Nasdaq that the Company's annual report on Form 20-F for the fiscal year ended June 30, 2025 was incomplete and that the Company is delinquent in its filing obligations. This was because such report failed to include an opinion from the Company's auditor, NLA DFK Assurance PAC, on the Company's financial statements. Pursuant to Listing Rule 5250(c)(1), companies shall timely file all required periodic financial reports with the United States Securities and Exchange Commission, and annual reports filed shall contain audited financial stat

Singapore, July 17, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL), today announced that it is putting on hold on the acquisition of BTC digital asset. After thorough discussions, Basel and the consortium of Bitcoin (BTC) holders have mutually agreed to pause the acquisition of digital asset. This decision reflects the ongoing regulatory review of digital assets by US authorities and the current lack of clarity on how forthcoming policies may impact the transaction. Given these uncertainties, both parties believe it is prudent to defer the deal until there is greater regulatory certainty. We will continue to monitor developments closely and reassess the opportunity once th

Singapore, June 26, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL) (the "Company"), today announced that Cathay Securities, Inc., as the representative of the several underwriters of the Company's initial public offering, has granted its consent on June 23, 2025 to the lock-up provision in the underwriting agreement dated February 24, 2025, permitting (i) a public offering or private placement of new securities of the Company, and (ii) the filing with the U.S. Securities and Exchange Commission of a registration statement under the Securities Act of 1933 in relation to such offering or placement, prior to the expiration of the lock-up period which was due to expire six mont

Singapore, May 29, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL), today reaffirmed the strength of its underlying financial performance and strategic outlook, despite recent volatility in its share price. Speaking on behalf of the Board and management team, BMGL's Chief Executive Officer, Dr Darren Chhoa stated, "While recent movements in our share price may raise questions, I want to assure our shareholders and stakeholders that the fundamentals of BMGL remain strong and resilient. Our financial performance continues to be robust, with our subsidiaries winning new sizable contracts particularly in the supply chain, and we remain on track with our acquisition growth strat

Singapore, May 22, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL), today announced that it has entered into a purchase agreement with a consortium of Bitcoin (BTC) holders for the purchase by the Company of up to 10,000 BTC (with current market value of approximately US$1.0 billion) by issuing of its ordinary shares. This purchase will diversify its treasury reserves to a very large extent, while maintaining its core focus on medical services expansion in the Asia Pacific Region. This is a major strategic financial initiative to strengthen the Company's balance sheet and support its aggressive expansion across Asia's high-growth healthcare markets. About Basel Medical Gro

Singapore, May 20, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL), today announced that its subsidiary has been awarded a significant contract worth S$375 million by Pancare Technology International (HK) Limited to supply essential healthcare products in Asia-Pacific over the next five years until October 31, 2029. This milestone underscores the Company's commitment to delivering high-quality medical solutions and strengthening its global presence in the healthcare sector. As part of the Company's strategic vision, the Company will be accelerating the integration of AI-powered technologies into its healthcare supply chain operations. This initiative aims to enhance efficie

Singapore, May 16, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL), today announced that it has begun exclusive negotiations for a US$1 billion BTC acquisition that will diversify its treasury reserves to a very large extent, while maintaining its core focus on medical services expansion. This is a major strategic financial initiative to strengthen its balance sheet and support its aggressive expansion across Asia's high-growth healthcare markets. Strategic Financial Restructuring for Growth BMGL is in advanced discussions with a consortium of institutional investors and high-net-worth individuals, who are influential in the crypto space, to acquire a US$1 billion BTC thro

Singapore , April 30, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL), today announced the closing of the acquisition of Bethesda Medical Pte. Ltd., a leading Singapore-based healthcare provider specializing in diagnostic imaging and outpatient care. The acquisition marks a significant step in Basel Medical Group's strategic expansion in Singapore and the broader Southeast Asian healthcare market. About Bethesda Medical Pte. Ltd. Bethesda Medical started its first medical establishment in 1995. This year marks their 30 years' anniversary, and at same time, marks the commencement of a new journey with Basel Medical Group. Bethesda Medical has previously won government tende

Singapore, April 11, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL), today announced the signing of a definitive agreement by its subsidiary Basel Medical Group Pte. Ltd. to acquire Bethesda Medical Pte. Ltd., a leading Singapore-based healthcare provider specializing in diagnostic imaging and outpatient care. The agreement marks a significant step in Basel Medical Group's strategic expansion in Singapore and the broader Southeast Asian healthcare market. The completion of the acquisition is subject to customary closing conditions and is expected to take place on or around April 30, 2025 or such other date agreed by the parties. Strategic Partnership Evolves into Full Inte

Singapore, March 19, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (the "Company") (NASDAQ:BMGL), a Singapore-based clinical provider of general and subspecialized orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments, today announced the full exercise of the overallotment option by the representative of the underwriters of its initial public offering to purchase an additional 330,750 ordinary shares at a price of US$4.00 per share and the closing of such issuance. The shares of the Company commenced trading on the Nasdaq Capital Market on February 25, 2025, under the ticker symbol "BMGL". The gross proceeds from this ov